Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Amgen (AMGN) one of those stocks right now? A quick glance at ...

Viridian Therapeutics shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza. The stock fell 21% to $14.73, extending some declines seen since reporting its own ...

Roche's strong drug growth is offsetting legacy declines, while strategic deals aim to reshape its portfolio amid biosimilar pressure and FX headwinds.

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 19, 2026, Wells Fargo raised ...

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen , Apogee Therapeutics and Gilead Sciences . Claim 30% Off TipRanks Premium. Unlock hedge fu ...

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want? One thing's for sure: You'll never discover truly ...